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tool for establishing large animal models of
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Zhuchi Tu1, Weili Yang1, Sen Yan1, Xiangyu Guo1* and Xiao-Jiang Li1,2*
Abstract
Animal models are extremely valuable to help us understand the pathogenesis of neurodegenerative disorders and
to find treatments for them. Since large animals are more like humans than rodents, they make good models to
identify the important pathological events that may be seen in humans but not in small animals; large animals are
also very important for validating effective treatments or confirming therapeutic targets. Due to the lack of
embryonic stem cell lines from large animals, it has been difficult to use traditional gene targeting technology to
establish large animal models of neurodegenerative diseases. Recently, CRISPR/Cas9 was used successfully to
genetically modify genomes in various species. Here we discuss the use of CRISPR/Cas9 technology to establish
large animal models that can more faithfully mimic human neurodegenerative diseases.
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Neurodegenerative diseases — Alzheimer’s disease(AD),-
Parkinson’s disease(PD), amyotrophic lateral sclerosis
(ALS), Huntington’s disease (HD), and frontotemporal
dementia (FTD) — are characterized by age-dependent
and selective neurodegeneration. As the life expectancy
of humans lengthens, there is a greater prevalence of
these neurodegenerative diseases; however, the patho-
genesis of most of these neurodegenerative diseases re-
main unclear, and we lack effective treatments for these
important brain disorders.
Genetic rodent models of neurodegenerative
diseases
Animal models provide us with a valuable system for
the study of neurodegenerative diseases. Transgenic
mouse models are particularly useful, since we have
versatile genetic tools available to modify the genomes
of mice to create loss- or gain-of-function models.
Most neurodegenerative diseases, such as AD, PD, and
ALS, are sporadic, and only a small percentage of
cases (4-5 %) are caused by genetic mutations [1–5].
However, HD is a monogenic mutation disease caused
by CAG repeat expansions in the IT15 gene, resulting
in expanded polyglutamine repeats in huntingtin (htt)
[6, 7]. Identification of the genetic mutations for dif-
ferent neurodegenerative diseases has enabled the gen-
eration of a variety of transgenic mouse models via
expression of mutant proteins. As a result, we now
have various mouse models of neurodegenerative dis-
eases from the expression of mutant genes under dif-
ferent promoters or from using other transgenic
approaches.
There are a number of excellent reviews covering dif-
ferent types of neurodegenerative diseases and their gen-
etic mouse models [8–12]. Investigations of different
mouse models of neurodegenerative diseases have re-
vealed a common pathology shared by these diseases.
First, the development of neuropathology and neuro-
logical symptoms in genetic mouse models of neurode-
generative diseases is age dependent and progressive.
Second, all the mouse models show an accumulation of
misfolded or aggregated proteins resulting from the ex-
pression of mutant genes. Third, despite the widespread
expression of mutant proteins throughout the body and
brain, neuronal function appears to be selectively or
preferentially affected. All these facts indicate that
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mouse models of neurodegenerative diseases recapitulate
important pathologic features also seen in patients with
neurodegenerative diseases.
However, it seems that mouse models can not recap-
itulate the full range of neuropathology seen in patients
with neurodegenerative diseases. Overt neurodegenera-
tion, which is the most important pathological feature in
patient brains, is absent in genetic rodent models of AD,
PD, and HD. Many rodent models that express trans-
genic mutant proteins under the control of different pro-
moters do not replicate overt neurodegeneration, which
is likely due to their short life spans and the different
aging processes of small animals. Also important are the
remarkable differences in brain development between
rodents and primates. For example, the mouse brain
takes 21 days to fully develop, whereas the formation of
primate brains requires more than 150 days [13]. The
rapid development of the brain in rodents may render
neuronal cells resistant to misfolded protein-mediated
neurodegeneration. Another difficulty in using rodent
models is how to analyze cognitive and emotional abnor-
malities, which are the early symptoms of most neurode-
generative diseases in humans. Differences in neuronal
circuitry, anatomy, and physiology between rodent and
primate brains may also account for the behavioral dif-
ferences between rodent and primate models.
Current large animal models of neurodegenerative
diseases
Several species have been used to create large animal
models of neurodegenerative diseases. Of these, pigs,
sheep, and non-human primates have been used success-
fully to establish HD, ALS, and PD animal models.
HD is caused by the expansion of a polyglutamine
(polyQ) repeat (>37 glutamines) in the N-terminal re-
gion of the disease protein huntingtin (htt) and is char-
acterized by preferential neuronal loss in distinct brain
regions [6, 14]. Numerous mouse models of HD have
been investigated extensively, revealing that N-terminal
fragments of mutant htt with expanded polyQ repeats
are toxic and form aggregates or inclusions in the brain
[15–24]. Transgenic HD pigs that express N-terminal
mutant htt consisting of the first 208 amino acids with
105Q (N208-105Q) were generated using nuclear trans-
fer technology [25]. Primary porcine fetal fibroblast cells
expressing N-terminal mutant htt fragments were used
for the nuclear transfer, and pig eggs containing these
nuclei were developed to early embryos that were then
transferred to surrogate pigs to produce newborn pigs.
Due to the overexpression of toxic N-terminal mutant
htt, most of the transgenic HD piglets died postnatally,
and some of them showed a severe chorea phenotype
before death. However, transgenic mice expressing the
same mutant htt could live up to 9 months, suggesting
that mutant htt is more toxic to larger animals [25].
More importantly, all transgenic pig brains had obvious
apoptotic cells, which have not been seen in the brains
of many HD mouse models. Interestingly, apoptotic
cardiomyocyte loss occurs in the absence of mutant htt
aggregates in cardiac tissue in R6/2 mice, suggesting
that this peripheral apoptotic event can be driven by
mutant htt-mediated CNS dysfunction [26]. In other
experiments, transgenic pigs expressing large htt frag-
ments with shorter polyQ expansion showed no obvious
neurological phenotypes, supporting the idea that
shorter htt fragments with larger polyQ expansions are
more toxic [27, 28]. Similarly, Jacobsen and colleagues
expressed transgenic full-length human htt cDNA con-
taining 73 CAG repeats in sheep under the control of
the human promoter by microinjection. One of the
founders showed robust expression of the full-length
human htt protein in both CNS and non-CNS tissue.
Although there was decreased expression of the neur-
onal marker DARPP-32 in medium-sized spiny neurons
in the striatum at 7 months, these full-length HD sheep
grow normally [29]. Thus, differences between full-
length and N-terminal htt transgenic large animals pro-
vide further evidence for the toxicity of N-terminal
mutant htt. Because of the gain-of-toxic function in
HD, current therapeutic approaches have been focused
on lowing mutant htt expression, including siRNA,
anti-sense oligonuelotides [30] as well as Zinc Finger
protein strategies [31]. These approaches, however, are
mainly applied to rodent models of HD. Thus, the de-
velopment of larger animal models might provide a use-
ful tool to validate the efficacy of ongoing pre-clinical
trials in rodents.
Amyotrophic lateral sclerosis (ALS) is an adult-onset,
progressive neurodegenerative disease characterized by
the selective death of motor neurons in the motor cor-
tex, brainstem, and spinal cord [32–34]. Most ALS
patients suffer from the sporadic form of ALS, with the
other 5 %-10 % of patients presenting with familial ALS.
Familial ALS could be caused by mutations in one of at
least 32 known genetic loci, including superoxide dis-
mutase 1 (SOD1), TAR DNA-binding protein 43 (TDP-
43), fused in sarcoma (FUS), and C9ORF72 [35–38].
The nuclear transfer method has also been used to es-
tablish cloned pigs expressing mutant SOD1 protein
with the ALS-associated SOD1 mutation G93A [39].
Transgenic SOD1 pigs show germline-transmissible
motor defects as well as neuronal degeneration that are
dose and age-dependent. More importantly, in the early
disease stage, mutant SOD1 did not form cytoplasmic
inclusions, but showed nuclear accumulation and ubi-
quitinated nuclear aggregates, which are seen in some
ALS patients, but not in transgenic ALS mouse models
[40–42]. This difference between transgenic ALS pigs
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and mice lends further support to the idea that pig
models can mimic some pathological events that occur
in patients, but not in mice.
It seems that aging is necessary for AD transgenic pigs
to develop impaired memory when the APPsw transgene
is expressed, since objective recognition was found to be
no different between AD transgenic pigs and controls at
1–2 years of age [43]. It is also possible that high expres-
sion levels of transgenic mutant protein are required to
facilitate disease progression in large animals.
Non-human primates would be a better model than
other animals to mimic the cognitive and emotional ab-
normalities seen in patients with neurodegenerative dis-
eases. Creation of the first transgenic monkey in 2001
demonstrated that the monkey genome could be genet-
ically modified [44–46]. Later, Yang et al. generated a
transgenic HD rhesus monkeys by injecting lentiviral
vector into fertilized oocytes to express exon1 mutant
htt with 84 CAG repeats [47]. Consistent with the path-
ology seen in HD mouse models and patients, transgenic
HD monkey brains also show abundant htt protein ag-
gregates in neuronal nuclei and neuronal processes.
However, unlike HD transgenic mice that express the
same exon1 mutant htt, HD transgenic monkeys experi-
ence mutant htt level-dependent postnatal death [47].
Furthermore, some HD monkeys develop key clinical
features of HD, including dystonia, chorea, and seizure,
which can not be found in mouse models or other small
animal models. More importantly, HD monkeys display
degeneration of axons and neuronal processes without
obvious cell body degeneration [25], suggesting that
neuronal degeneration in HD may initiate from neuronal
processes.
Transgenic monkeys that express mutant α-synuclein to
model Parkinson’s disease (PD) have also been established
recently [48]. PD is an age-dependent neurodegenerative
disease with late-onset degeneration of dopaminergic neu-
rons in the substantia nigra, which leads to a complex
motor disorder characterized by bradykinesia, tremor, ri-
gidity, and postural instability. Lewy body inclusions,
which are composed mainly of α-synuclein and ubiquitin,
and selective loss of dopamine (DA) neurons in the sub-
stantia nigra pars compacta are the pathologic and ana-
tomical hallmarks of PD [49–51]. Rodent and other small
animal models replicate the pathological and clinical fea-
tures of human Parkinsonism only partially [52, 53]. For
example, most transgenic PD mice show no loss of sub-
stantia nigra dopaminergic neurons [54]. By expressing
mutant α-synuclein(A53T)in transgenic rhesus monkeys
via lentiviral vector expressing A53T in fertilized monkey
embryos, we obtained six transgenic A53T monkeys. After
the age of 2.5 years, the oldest transgenic A53T monkey
started to show age-dependent non-motor symptoms, in-
cluding cognitive defects, an anxiety phenotype, and poor
fine finger coordination and dexterity [48]. These behav-
ioral phenotypes of the A53T monkey are consistent with
the non-motor symptoms of PD patients at the early dis-
ease stage [48, 51, 55]. The transgenic A53T monkeys
demonstrate the age-dependent non-motor symptoms
caused by mutant α-synuclein and offer insight into treat-
ment for early PD. Consistent with the age-dependent
neuropathology seen in PD, stereotaxic injection of lenti-
viral vectors expressing A53T in the substantial nigra of
monkeys at different ages also revealed that aging pro-
motes neuropathology in non-human primate brains [56].
Transgenic large animal models thus provide us with valu-
able information about disease pathogenesis and neuro-
pathology that may not be identified in rodent or small
animal models.
CRISPR/Cas9 as a new tool for generating large animal
models of neurodegenerative diseases
The previously established large animal models of neuro-
degenerative diseases have been used to mimic gains of
toxic function of mutant proteins. This is because the
transgenic approaches used allow for the expression of
extra copies of mutant genes under the exogenous pro-
moters; however, many human diseases, including neuro-
degenerative disorders, are caused by genetic mutations in
endogenous genes. Due to the lack of embryonic stem cell
lines from large animals for genomic manipulation, it has
been difficult to create large animal disease models by
genetically modifying endogenous genes. Fortunately, re-
cent developments in genome editing with new technolo-
gies now make it possible to establish large animal models
to investigate neurodegenerative diseases.
The CRISPR(clustered regularly interspaced short pal-
indromic repeats)/Cas9 system is a novel genome modi-
fication method in which guide RNAs (gRNA)direct the
nuclease Cas9 to selected sequences of genomic DNA,
and Cas9 cuts both strands at a precise location. The
genomic DNA is then repaired by non-homologous end
joining (NHEJ) or homology-directed repair (HDR),
resulting in mutations that can interrupt the open read-
ing frame and cause gene inactivation. To simplify the
process of constructing the CRISPR/Cas9 system and to
keep its cleavage efficacy, the dual-crRNA:tracrRNA
complex was designed as a single transcript (single-guide
RNA or sgRNA) that is required for Cas9’s binding and
cutting DNA targets to introduce double-strand breaks
(DSBs) (Fig. 1). CRISPR/Cas9 has now become a simple
and versatile RNA-directed system for genome editing in
a wide range of different organisms and cell types, in-
cluding bacteria, mice, rat, zebrafish, pig, human somatic
cells, and human pluripotent stem cells [57–61]. Several
groups in China recently used CRISPR/Cas9 to genetic-
ally modify genomes in embryos from pigs [62, 63] and
monkeys [64–67]. These studies proved that CRISPR/
Tu et al. Molecular Neurodegeneration  (2015) 10:35 Page 3 of 8
Cas9 is an efficient tool to genetically modify genomic
DNAs in germline cells without the need to establish
embryonic stem cells for genomic manipulation.
Transcription activator-like effector nucleases (TALENs)
have also been recently used for genomic editing. TALENs
are chimeric proteins consisting of a programmable DNA-
binding domain fused to the Fok1 nuclease domain, allow-
ing for cutting double strand DNAs at any desired se-
quences [68, 69]. Because the binding of TALEN to the
targeted DNA relies on its DNA binding domain that is
composed of multiple repeat units, each repeat containing
33–35 amino acids, TALENs is thought to have less off-
target effect [70]. However, assembling TALEN targeting
vectors requires much more efforts than generating
CRISPR/Cas9 targeting vectors, making CRISPR/Cas9 a
more widely used tool for genomic editing. In this review,
we focus on the utilization of CRISPR/Cas9 in establishing
large animal models of neurodegenerative diseases.
Advantages and limitations of CRISPR/Cas9 in large
animals
One advantage of CRISPR/Cas9 is that it can create muta-
tions at virtually any location in genomic DNA [60, 71–73].
In the CRISPR/Cas9 system, a guide RNA hybridizes a 20-
nt DNA sequence immediately preceding an NGG DNA
motif (protospacer-associated motif or PAM), resulting in a
double-strand break (DSB) 3 bp upstream of the NGG
(Fig. 1). Because this targeting relies on 23 base pair
matches, CRISPR/Cas9 can target to virtually any genes in
a sequence-dependent manner. As a result, CRISPR/Cas9
can target two alleles to cause a null mutation in the
founder animals. Such an advantage is particularly import-
ant for generating large animal models of diseases since the
extended time to breed large animals does not allow for
quick mating of heterozygous mutant animals to generate
homozygous mutants. In addition, since CRISPR/Cas9 can
disrupt two alleles in female animals, the female animals
can also show phenotypes due to the complete loss of func-
tion of the targeted gene, even if the disease gene is X-
linked inherited. To ensure that two alleles are disrupted,
multiple sites of the desired gene can be targeted by
CRISPR/Cas9. In this regard, CRISPR/Cas9 makes a power-
ful tool for generating non-human primate or large animal
models of neurodegenerative diseases that are caused by
the loss of function of specific genes.
However, because targeting by CRISPR/Cas9 relies on
approximate 23 base pair matches [74], CRISPR/Cas9 may
generate a number of nonspecific mutations in the gen-
ome. Such nonspecific mutations can be diluted over gen-
erations in small animals with short breeding times, but
for large animals like monkeys, their sexual maturation
usually requires 4–5 years; thus the off-target issue is crit-
ical in large animals and can confound the phenotypes of
founder animals caused by targeting the desired gene.
Fig. 1 CRISPR-Cas9 targeting system. In the CRISPR/Cas9 system, a guide RNA hybridizes a 20-nt DNA sequence immediately preceding an NGG DNA
motif (protospacer-associated motif or PAM), resulting in a double-strand break (DSB) 3 bp upstream of the NGG. The double-stranded DNA breaks
become substrates for endogenous cellular DNA repair machinery that catalyze nonhomologous end joining (NHEJ) or homology-directed repair (HDR).
Adopted from Charpentier & Doudna, Nature, 2013,495:50–1
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The second issue with CRISPR/Cas9 is mosaic muta-
tions, or different types of mutations generated in differ-
ent cells. Mosaic mutations may affect the generation of
animal models of genetic human diseases because a spe-
cific genetic mutation in a human disease often occurs
at the one-cell stage before cell division, such that the
same mutation is present ubiquitously in every individ-
ual cell. The mechanism behind these mosaic mutations
remains unknown. It is possible that the translation of
Cas9 mRNA to produce an active enzymatic form is de-
layed until after the first cell division, and this delay may
play a major role in genetic mosaicism [74–77]. The mo-
saicism problem may also result from the prolonged ex-
pression of Cas9 mRNA. Alternatively, differential DNA
repair and non-homozygous recombination activities in
zygotes and divided embryonic cells can also influence
genetic mutation rates and mosaicism. Despite the un-
known mechanisms behind mosaicism, mosaic muta-
tions can result in loss of function if they disrupt the
expression of functional proteins. Evidence for this
comes from a Duchenne muscular dystrophy (DMD)
monkey model [65], in which three different mutations
in the dystrophin gene cause the loss of dystrophin in
monkey muscle and muscle atrophy, as seen in DMD
patients [78, 79]. Thus, if mosaic mutations in large ani-
mals result in loss of function, the mutant animals may
show pathology similar to that caused by a monogenic
mutation in human diseases.
Although CRISPR/Cas9 has been used to generate
knock-in mutations in various species, this knock-in rate
is much lower than the random indel mutation rate be-
cause the knock-in requires the precise homologous re-
combination of the donor DNA. Thus, the current
application of CRISPR/Cas9 is used mainly to create
random mutations in the targeted genes to induce loss-
of-function phenotypes in animal models.
Use of CRSPR/Cas9 to generate large animal models of
neurodegenerative diseases
The ability of CRISPR/Cas9 to directly target any gene
in the embryo genome opens up a new avenue for us to
generate animal models of neurodegenerative diseases,
especially large animal models that often require the in-
vestigation of founder animals. As we discussed above,
CRISPR/Cas9 can cause mutations in one or two al-
leles, which can mimic heterozygous or homozygous
knockout of a specific gene. Some neurodegenerative
diseases, such as PD, can be caused by loss of function
due to mutations in the Parkin and Pink1 genes. These
genes can be targeted by CRISPR/Cas9 in non-human
primates or other large animals to inactivate gene ex-
pression. When both alleles are mutated, the complete
loss of Parkin or Pink1 will mimic the genetic muta-
tions in PD patients. To ensure that two alleles will be
disrupted, multiple targeting regions can be designed,
with a few gRNAs for co-injection with Cas9 into fertil-
ized eggs at the one-cell stage.
Many neurodegenerative diseases are also caused by a
gain of toxicity of mutant proteins. For example, PD can
be caused by mutations in α-synuclein, and HD is
caused by polyQ expansion in htt. To generate animal
models of such diseases will require knock-in mutations
in the genes encoding for the disease proteins. Although
the current knock-in rate with CRISPR/Cas9 is low, rap-
idly developing technology has improved its knock-in ef-
ficiency. For example, the use of inhibitors of NHEJ
significantly increased the knock-in rate in mammalian
cells [80]. Recently, direct nuclear delivery of Cas9 pro-
tein complex with chemically synthesized dual RNA was
reported to generate knock-in mice with up to 50 % effi-
ciency [81]. Thus, the newly developed CRISPR/Cas9
system holds great promise for use in non-human pri-
mates and large animals to generate knock-in models of
human diseases or to modify specific genes.
The off-target and mosaic issues in large animal models
need to be considered carefully. This is because large ani-
mals like monkeys need to be analyzed before producing
offspring; thus, the off-target issue is critical and can con-
found the phenotypes of founder animals. Because off-
target events were not seen in established CRISPR/Cas9-
targeted monkeys [40–42], it is likely that any off-target
effect is quite minimal and can be prevented by designing
highly selective gRNA containing adequate mismatched
base pairs with other genes. Use of bioinformatic screen-
ing to search for unique genomic targets and use of paired
Cas9 nickases can also reduce off-targets [59, 82]. Because
promotion of HDR over NHEJ has been found to increase
knock-in targeting [80, 83], drugs or chemicals that are
able to increase this promotion should also help decrease
the frequency of off-targets and increase knock-in rate.
If we want to create animal models with loss-of-
function phenotypes, mosaic mutations can achieve this
goal by disrupting gene function. It is important, how-
ever, to ensure that the targeted gene has lost its func-
tion. We have recently shown that indel mutations in
more than 87 % of the monkey dystrophin gene is suffi-
cient to lead to the loss of expression of dystrophin and
consequently results in muscle degeneration as seen in
Duchenne muscular dystrophy (DMD) [65]. Thus, quan-
tification of the rates of mosaic mutations, especially
those that can disrupt gene expression, is important to
assess the functional inactivation of the targeted gene.
Given that DNA repair mechanisms may not be iden-
tical in germline and postmitotic neuronal cells, it re-
mains unclear whether there are lower mosaic mutation
rates in mature neuronal cells in adult animals. Since
CRISPR/Cas9 can also target genes in adult neuronal
cells [84–86], it can be applied to the brains of adult
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animals via stereotaxic injection of viral expression vec-
tors. Such application may limit mosaic and off-target
effects to the injected brain region, and more import-
antly, will enable us to examine brain regional effects of
mutant genes. Also, by comparing animals at different
ages, age-dependent effects of mutant genes can be
assessed. Such studies may be particularly useful for
large animals to mimic distinct and age-dependent neu-
rodegeneration, which is a pathological feature in differ-
ent types of neurodegenerative diseases. Also, direct
administration of gRNA/Cas9 into specific brain regions
of adult large animals to modify neuronal genes does
not involve genetic manipulation in germline cells and
the extended time for animal development and matur-
ation, which could be an alternative method to rapidly
generate large animal models of neurodegenerative
diseases.
It should also be pointed out that analysis of the phe-
notypes of large animal models requires further develop-
ment of behavioral assays that can be applied to large
animals. Also, the number of large animals generated
with genetic modification is often not sufficient to pro-
vide rigorous statistical analyses. All these obstacles re-
main to be overcome so that large animal models can be
more widely utilized.
Conclusions
Transgenic approach and CRISPR/Cas9 can be used to
generate large animal models of diseases, such as non-
human primate models of neurodegenerative disease
(Fig. 2). CRISPR/Cas9 is a new genome modification tool
that can efficiently and readily target any gene in the
genome in germline cells and somatic cells of different
species. Thus, CRISPR/Cas9 makes it possible to imple-
ment genome editing in non-human primates and large
animals to generate genetic mutations that can faithfully
mimic pathology in human patients. Because of the abil-
ity of CRISPR/Cas9 to disrupt two alleles, this system
can make it possible for founder animals to be investi-
gated for loss of function of the targeted gene. Off-target
and mosaic mutations need to be considered when using
CRISPR/Cas9. Despite great advances in genome editing,
the knock-in rate via CRISPR/Cas9 is still low with
current technology. However, new tools for genome edit-
ing are being developed quickly and will significantly im-
prove the targeting rate and reduce off-target and
mosaic mutation effects. The newly developed CRISPR/
Ca9 technology will promote the generation of non-
human primates and large animal models of neurode-
generative diseases and enhance our understanding of
the pathogenesis of these important diseases.
Fig. 2 Establishment of non-human primate models of neurodegenerative diseases. In non-human primates, female monkeys are superovulated for
collection of eggs, which are subject to intracytoplasmic sperm injection (ICSI) for in vitro fertilization. The fertilized eggs are injected with either lenti-
viral vectors into perivitelline space to express exogenous transgenes or gRNAs/Cas9 into cytoplasm to target the endogenous genes. The injected
eggs then developed to 4- or 8-cell embryos in vitro before being transferred to the surrogate monkeys. After full-term gestational development, the
newborn monkeys are examined to verify the presence of transgenes of mutations in the targeted DNAs, which are known to cause neurodegenerative
diseases in humans
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